Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25214308 | 0.90 | FAAH (0.45) | FAAHUSP30HDAC1HDAC6CA12 | |
| SCHEMBL25218982 | 0.89 | FAAH (0.49) | FAAHUSP30HDAC1HDAC6CA12 | |
| SCHEMBL22557053 | 0.89 | FAAH (0.47) | FAAHUSP30HDAC1HDAC6CA12 | |
| SCHEMBL25241218 | 0.88 | FAAH (0.42) | FAAHUSP30HDAC1HDAC6CA12 | |
| SCHEMBL25215762 | 0.88 | FAAH (0.42) | FAAHUSP30HDAC1HDAC6CA12 | |
| SCHEMBL22557556 | 0.88 | FAAH (0.46) | FAAHUSP30HDAC1HDAC6CA12 | |
| SCHEMBL25215099 | 0.87 | FAAH (0.43) | FAAHUSP30HDAC1HDAC6CA12 | |
| SCHEMBL22557010 | 0.87 | FAAH (0.45) | FAAHUSP30HDAC1HDAC6CA12 | |
| SCHEMBL22557064 | 0.85 | FAAH (0.48) | FAAHUSP30HDAC1HDAC6CA12 | |
| SCHEMBL30473927 | 0.85 | FAAH (0.41) | FAAHUSP30HDAC1HDAC6LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2025-01-30 | — | — | US | claimed |
| EP-4441044-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | claimed |
| CN-118302422-A | Substituted N-cyanopyrrolidines having activity as USP30 inhibitors | 特殊治疗有限公司 | 2024-07-05 | — | — | CN | claimed |
| WO-2023099561-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-06-08 | — | — | WO | claimed |
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2025-01-30 | — | — | US | disclosed |
| EP-4441044-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| CN-118302422-A | Substituted N-cyanopyrrolidines having activity as USP30 inhibitors | 特殊治疗有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023099561-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023099561-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP47, USP1 | FAAH 1830/4885USP30 1/4885HDAC1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.